MedTrace Logo

Clinical Trial on Pharmacokinetics and Tolerability of AP707

NCT05267769 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2022-07-27

No results posted yet for this study

Summary

Brief Summary:This study aims to investigate the uptake of AP707, a preparation from cannabis flowers, into the bloodstream after in single administration in healthy volunteers.

Conditions

  • Pharmacokinetics
  • Tolerability
  • Safety

Interventions

DRUG

AP707

Preparation of Cannabis flowers (Cannabis flos)

Sponsors & Collaborators

  • CannaXan GmbH

    lead INDUSTRY

Principal Investigators

  • Stefan Lorenzl, Prof. Dr. · Phase I Unit of CannaXan GmbH

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-02
Primary Completion
2022-04-03
Completion
2022-04-03

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05267769 on ClinicalTrials.gov